Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Ahead of print articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 25, Number 11—November 2019
Letter

Macrolide-Resistant Mycoplasma genitalium in Southeastern Region of the Netherlands, 2014–2017

Suggested citation for this article

To the Editor: We read with interest the article by Martens et al., which analyzed the frequency of macrolide resistance–mediating mutations in Mycoplasma genitalium infections in the southeastern region of the Netherlands during 2014–2017 (1). Authors reported high rates of macrolide resistance in M. genitalium infections (281/827; 34.0%) and observed a decrease in the rate in 2017 (115/290; 39.7%) compared with 2016 (92/207; 44.4%), after an increase in the number of tests of cure performed.

Increasing rates of macrolide resistance in M. genitalium are a problem not only in Netherlands but also worldwide: 77.4% in New Zealand (2) and 41% in United Kingdom (3). Macrolide resistance in M. genitalium as a consequence of single-dose azithromycin treatment has been previously reported (4). European Academy of Dermatology and Venereology guidelines recommend azithromycin in an extended regimen (500 mg day 1, 250 mg days 2–5, orally) as a first-line treatment, followed by a test of cure 4–6 weeks after treatment (5).

In northern Spain, local protocols for the treatment of M. genitalium infections are based on the European guideline. We performed a prospective/retrospective study during August 2015–October 2018. We confirmed 173 cases of M. genitalium infection; mean patient age was 29.4 years, and 57.2% (99/173) were male. We found macrolide-resistant M. genitalium strains in 21.8% (27/124) patients, which is a lower rate than was found in the Netherlands. Most of the patients attending posttreatment follow-up showed wild-type M. genitalium, and only 10.9% (5/46) became resistant to azithromycin treatment, in contrast with 89.6% (60/67) reported by Martens et al. We suggest that the decrease in macrolide resistance resulted from the increased number of posttreatment follow-ups. Our data confirm this. We believe that giving local advice on the basis of extended azithromycin treatment and posttreatment follow-up can limit the spread of macrolide resistance.

Top

Marta AdelantadoComments to Author , Ana Navascués, Xabier Beristain, Alberto Gil-Setas, Maria E. Portillo, Aitziber Aguinaga, and Carmen Ezpeleta

Author affiliations: Complejo Hospitalario de Navarra Department of Clinical Microbiology, Pamplona, Spain

Top

References

  1. Martens  L, Kuster  S, de Vos  W, Kersten  M, Berkhout  H, Hagen  F. Macrolide-resistant Mycoplasma genitalium in southeastern region of the Netherlands, 2014–2017. Emerg Infect Dis. 2019;25:1297303. DOIPubMed
  2. Anderson  T, Coughlan  E, Werno  A. Mycoplasma genitalium macrolide and fluoroquinolone resistance detection and clinical implications in a selected cohort in New Zealand. J Clin Microbiol. 2017;55:32428. DOIPubMed
  3. Pond  MJ, Nori  AV, Witney  AA, Lopeman  RC, Butcher  PD, Sadiq  ST. High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. Clin Infect Dis. 2014;58:6317. DOIPubMed
  4. Jensen  JS, Bradshaw  CS, Tabrizi  SN, Fairley  CK, Hamasuna  R. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis. 2008;47:154653. DOIPubMed
  5. Jensen  JS, Cusini  M, Gomberg  M, Moi  H. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2016;30:16506. DOIPubMed

Top

Suggested citation for this article: Adelantado M, Navascués A, Beristain X, Gil-Setas A, Portillo ME, Aguinaga A, et al. Macrolide-resistant Mycoplasma genitalium in southeastern region of the Netherlands, 2014–2017. Emerg Infect Dis. 2019 Nov [date cited]. https://doi.org/10.3201/eid2511.190912

DOI: 10.3201/eid2511.190912

Original Publication Date: 8/22/2019

Related Links

Top

Table of Contents – Volume 25, Number 11—November 2019

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Marta Adelantado Lacasa, Complejo Hospitalario de Navarra Department of Clinical Microbiology, Calle Irunlarrea s/n. 31008 Pamplona, Navarra, Spain

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: August 22, 2019
Page updated: August 22, 2019
Page reviewed: August 22, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external